Faster Access to Clinical Trials via NHS App
Patients with rare cancers, including brain cancers, are set to receive faster access to life-changing clinical trials through the NHS App. This significant initiative forms a core part of the government's new National Cancer Plan and aligns closely with the ongoing Rare Cancers Bill, which was introduced by Dr. Scott Arthur MP.
"Patients with rare cancers, including brain cancers, are set to receive faster access to life-changing clinical trials through the NHS App."
Initially, patients will be empowered to search for trials using a dedicated clinical research database and will have the option to request contact regarding relevant opportunities. Future enhancements to the app are planned to enable patients to automatically receive details of potentially beneficial clinical trials, streamlining the process even further. The broader expansion of the NHS App aims to cultivate a digitally-enabled health service, encompassing everything from booking appointments and managing care to accessing crucial research notifications.
Government Initiatives and Funding
The government is actively prioritizing previously neglected rare cancers, a commitment underscored by the appointment of new national leads in this area. The Rare Cancers Bill is specifically designed to incentivize vital research and investment in treatments for rare cancers. Its overarching goal is to ensure more consistent access to research findings and to accelerate the progression from initial discovery to tangible patient treatment. This strategic focus also includes recruiting more cancer experts for key national roles.
Since July 2024, brain cancer research has received a substantial financial boost, amounting to £32.3 million. This significant funding injection will be used to support the development and enhancement of clinical trials, with a particular focus on innovative precision medicine treatments. Furthermore, it will facilitate the provision of tailored care and foster the development of the next generation of leaders in brain cancer research. The National Institute for Health and Care Research (NIHR) will establish a new Speciality Lead for Rare Cancers to oversee a comprehensive program. This program will be dedicated to facilitating clinical trials across England and ensuring that rare cancer patients are automatically contacted about relevant research opportunities.
Partnerships and Future Goals
The government is strengthening its vital partnership with Cancer Research UK (CRUK), which includes a £3 million co-funding commitment for the CRUK Brain Tumour Centres of Excellence, commencing this year. These specialized centers are poised to drive cutting-edge research, improve treatment methodologies, and ultimately enhance survival rates for both children and adults affected by brain tumors.
Looking ahead, the government aims for the UK to become a leader in Europe for the survival rates of 14 less common and deadliest cancers, including brain cancer, by 2035. Complementing this ambitious goal are plans to establish a Cancer Clinical Trials Accelerator, which will be hosted by the NIHR Industry Hub. This accelerator is designed to significantly improve the speed, reliability, size, and scope of cancer trials, bringing new hope to patients sooner.
Increased investment in the NIHR Brain Tumour Research Consortium, now expected to reach up to £25.5 million, brings together an impressive network of 48 organizations. This consortium will deliver a nationally coordinated research program, specifically designed to accelerate the development and rigorous evaluation of new brain cancer treatments for both adults and children.